Stocks · News reference

Apollomics Announces Layoffs and Termination of Lung Cancer Trial Due to Cash Constraints

2026-11-08 14:03:06 UTC

Apollomics Inc. has terminated its entire U.S. workforce, including its CEO and CFO, and plans to halt all activities related to its lung cancer clinical trial due to severe liquidity issues.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

APLM

Source: fiscal.ai
Observed: 2026-11-08 14:03:06 UTC
Checked: 2026-11-08 14:04:20 UTC
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

Benzinga2026-08-11 21:06:27 UTCBenzinga Insights
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Dermata Therapeutics (NASDAQ:DRMA) stock moved upwards by 44.4% to $1.56 during Tuesday's after-market session. The company's market cap stands at $4.5 million. As per the news, the Q2 earnings report
ABSI APLM ARAY CCM CRDF
Benzinga2026-08-11 20:39:43 UTCBenzinga Newsdesk
Apollomics Announces $10M Private Placement Of Up To 700,001 Class A Ordinary Shares At $15 Per Share, Including $2M Note Conversion By CEO Howard Chen
APLM

Apollomics Announces Layoffs and Termination of Lung Cancer Trial Due to Cash Constraints

Connected Markets

Related Headlines

12 Health Care Stocks Moving In Tuesday's After-Market Session

Apollomics Announces $10M Private Placement Of Up To 700,001 Class A Ordinary Shares At $15 Per Share, Including $2M Note Conversion By CEO Howard Chen